Flecainide or Sotalol or Propafenone — Competitive Intelligence Brief

Flecainide or Sotalol or Propafenone (Flecainide or Sotalol or Propafenone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiarrhythmic agents (Class I and Class III). Area: Cardiovascular.

phase 3 Antiarrhythmic agents (Class I and Class III) Cardiac sodium channels (Flecainide, Propafenone); cardiac potassium channels and beta-adrenergic receptors (Sotalol) Cardiovascular Small molecule

Target snapshot

Flecainide or Sotalol or Propafenone (Flecainide or Sotalol or Propafenone) — Medtronic Cardiac Rhythm and Heart Failure. These antiarrhythmic drugs suppress abnormal heart rhythms by blocking sodium and/or potassium channels in cardiac tissue, slowing electrical conduction and prolonging the refractory period.

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Flecainide or Sotalol or Propafenone TARGET	Flecainide or Sotalol or Propafenone	Medtronic Cardiac Rhythm and Heart Failure	phase 3	Antiarrhythmic agents (Class I and Class III)	Cardiac sodium channels (Flecainide, Propafenone); cardiac potassium channels and beta-adrenergic receptors (Sotalol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiarrhythmic agents (Class I and Class III) class)

1. Medtronic Cardiac Rhythm and Heart Failure · 1 drug in this class